• We are dedicated to supporting the discovery and development of novel diagnostics and prognostic assays that help to save lives and improve the quality of life of cancer patients. We are dedicated to supporting the discovery and development of novel diagnostics and prognostic assays that help to save lives and improve the quality of life of cancer patients.
  • We are dedicated to supporting the discovery and development of novel diagnostics and prognostic assays that help to save lives and improve the quality of life of cancer patients. We are dedicated to supporting the discovery and development of novel diagnostics and prognostic assays that help to save lives and improve the quality of life of cancer patients.
  • We are dedicated to supporting the discovery and development of novel diagnostics and prognostic assays that help to save lives and improve the quality of life of cancer patients. We are dedicated to supporting the discovery and development of novel diagnostics and prognostic assays that help to save lives and improve the quality of life of cancer patients.
  • We are dedicated to supporting the discovery and development of novel diagnostics and prognostic assays that help to save lives and improve the quality of life of cancer patients. We are dedicated to supporting the discovery and development of novel diagnostics and prognostic assays that help to save lives and improve the quality of life of cancer patients.

Partnering

OncoMark PartneringOncoMark has invested in R&D and in-licensing of IP for diagnostic assay development. We believe that partnering should begin as early as possible in the development process.

Every winning partnership starts with a simple decision Click for more details »

 Products

IHC-Mark and Biomarker Interpretation Workflow 

OncoMark's lead product in development is OncoMasTR, a novel prognostic assay for early breast cancer. 

This multi-biomarker panel will determine the risk of recurrence for early breast cancer patients as either high or low risk.

The assay will aid the clinicians to determine the best option treatments for their patients.

 
View current products »
 

Research Projects



 

 

Subscribe to RSS FeedCompany News

June 2017: OncoMark wins a Champions of EU Research award
OncoMark CEO Des O'Leary was awarded an Ireland's Champions of EU Research award from Enterprise Ireland at an event held in the Royal Hospital Kilmainham yesterday (Wednesday 28th June 2017). » read more
May 2017: OncoMark Researchers Shed Light on the Discovery and Validation of Master Transcriptional Regulators in Cancer
OncoMark researchers have recently had a review published in the American Association for Cancer Research (AACR) journal, Cancer Research, describing how the reverse engineering of transcriptional networks using gene expression data enables the identification of genes that underpin the development and progression of different cancers. » read more
May 2017: OncoMark looking for an applicant for a Marie Sklodowska-Curie Enterprise Fellowship
OncoMark are actively looking for a talented researcher to apply for a Marie Curie Individual Fellowship under the MSCA Enterprise Call. We would welcome researchers and / or research proposals across several areas of cancer research including breast cancer, colorectal cancer, prostate cancer and melanoma. » read more
Feb 2017: OncoMark Secures €2.1 Million Investment to Commercialise New Diagnostic Test for Breast Cancer
OncoMasTR test to launch in 2018 and will reduce the number of patients receiving unnecessary chemotherapy » read more
March 2017: Prof. William Gallagher Awarded Prestigious Medal for Outstanding Contribution to Irish Cancer Research
Congratulations to Professor William Gallagher, who was the inaugural recipient of the Irish Association of Cancer Research (IACR) Cancer Research Medal at the annual IACR Conference held in Kilkenny on 22nd-24th February 2017. This prestigious award recognises his outstanding contribution to the cancer research community in Ireland throughout his career. » read more